Finnland - finnska - Fimea (Suomen lääkevirasto)

norbrook laboratories (ireland) limited - carprofen - injektioneste, liuos - 50 mg/ml - karprofeeni

Evrópusambandið - finnska - EMA (European Medicines Agency)

pharmaand gmbh - darifenasiinihydrobromidia - urinary incontinence, urge; urinary bladder, overactive - urologicals, lääkkeitä virtsan taajuus ja inkontinenssi - oireenmukaista hoitoa pakkoinkontinenssin ja/tai lisääntynyt virtsaamistarve ja pikaisesti, kuten voi tapahtua aikuispotilailla, joilla on yliaktiivinen rakko.

Evrópusambandið - finnska - EMA (European Medicines Agency)

eli lilly and company limited  - fentanyyli - hermosto - koirat - ortopedisen ja pehmytkudoksen leikkaukseen liittyvien kivun kontrolloimiseksi koirilla.

Evrópusambandið - finnska - EMA (European Medicines Agency)

crealta pharmaceuticals ireland limited - pegloticase - kihti - antigout-valmisteet - krystexxa on tarkoitettu kohtelu vaikea heikentävä krooninen tophaceous kihti aikuisilla, jotka voi olla erosive osallistuminen ja jotka eivät ole normalisoida seerumin virtsahappo ksantiiniguaniinifosforibosyylitransferaasin monoamiinioksidaasin estäjiä suurimmalla lääketieteellisesti sopiva annos tai jolle nämä lääkkeet ovat vasta.

Evrópusambandið - finnska - EMA (European Medicines Agency)

hra pharma rare diseases - mitotaanin - adrenal cortex neoplasms - antineoplastiset aineet - kehittyneiden (tarttumattomien, metastaattisten tai relapsoitujen) lisämunuaisen kortikaalisen karsinooman oireenmukainen hoito. lysodrenin vaikutusta ei-toiminnalliset lisämunuaisen kuorikerroksen karsinooman hoidossa ei ole osoitettu.

Evrópusambandið - finnska - EMA (European Medicines Agency)

glaxosmithkline dungarvan limited - esomepratsoli - gastroesofageaalinen refluksi - protonipumpun estäjät - nexium control on tarkoitettu lyhytkestoisen refluksi-oireiden hoitoon (esim. närästys ja hapon regurgitaatio) aikuisilla.

Evrópusambandið - finnska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - immunosuppressantit - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.

Evrópusambandið - finnska - EMA (European Medicines Agency)

janssen-cilag international nv - darunaviiria - hiv-infektiot - antiviraalit systeemiseen käyttöön - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.